Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure
- 17 July 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 116 (3) , 249-257
- https://doi.org/10.1161/circulationaha.107.694562
Abstract
Background— Cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) have been used to estimate prognosis in heart failure; however, most studies have evaluated decompensated patients with single measurements. To determine if there are advantages to serial measurements, we evaluated stable chronic heart failure patients every 3 months for 2 years.Keywords
This publication has 31 references indexed in Scilit:
- Reliability of Ventricular Remodeling as a Surrogate for Use in Conjunction With Clinical Outcomes in Heart FailureThe American Journal of Cardiology, 2005
- Practical recommendations for the use of ACE inhibitors, beta‐blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practiceEuropean Journal of Heart Failure, 2005
- Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implicationsInternational Journal of Cardiology, 2005
- Ongoing Myocardial Injury in Stable Severe Heart FailureCirculation, 2004
- N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure PatientsCirculation, 2004
- Biochemical markers of myocyte injury in heart failureHeart, 2004
- Severity of left ventricular remodeling defines outcomes and response to therapy in heart failureJournal of the American College of Cardiology, 2004
- Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart FailureNew England Journal of Medicine, 2004
- Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVFEuropean Journal of Heart Failure, 2003
- Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)Circulation, 2003